Gechai decoction for antipyretic effect and safety evaluation of COVID-19

INTERVENTION: Gechai Tangfang Group:Take Gechai Tangfang;Western medicine group:Take Tylenol; CONDITION: Covid‐19 PRIMARY OUTCOME: Time to onset of defervescence;Body temperature after the drug; SECONDARY OUTCOME: Number of doses;Daily morning body temperature;Daily morning heart rate;Daily morning breathing rate;Daily morning oxygen saturation;Heat syndrome;Cold syndrome;Sweat syndrome;Head and body syndrome;Urination conditions;Stool conditions;Taste situation;Stomach condition;Cough and phlegm;Symptoms of palpitation and chest tightness;Symptoms of pharyn Xnose and mouth;Drinking;Sleep conditions;Adverse reactions: flushing of the complexion;Adverse effects: edema;Adverse reactions: body erythema;Adverse reactions: burning sensation;Adverse effects: nausea and vomiting;Adverse effects: abdominal pain and diarrhea;Cure rate;Excellent effect rate;Effectual rate;Ineffectual rate; INCLUSION CRITERIA: 1. Patients with mild and ordinary types who are infected by the new coronavirus; 2. Symptoms include no sweat, fever, chills, nasal congestion, runny nose, sore throat, itchy throat, headache, body pain, nausea, vomiting and other three yang combinations; 3. Body temperature >= 38.5 °C; 4. Age 18‐75 years old, gender is not limited; 5. Within 48 hours of onset; 6. Western medicines, proprietary Chinese medicines, and traditional Chinese medicines that have not been used after the onset of the disease; 7. No cognitive impairment, able to understand and communicate correctly; 8. Those who sign the informed consent form, cooperate with the treatment, and can adhere to the completion of all treatment as planned.